United States Biosimilar Industry Market Outlook to 2030: Size, Share, Growth and Trends

The United States Biosimilar Industry Market was valued at USD 11,200 Mn in 2024 on a manufacturer and commercialization net sales basis. This size reflects a market that has already moved beyond early supportive-care substitution and now includes meaningful revenue pools in oncology, immunology, insulin, ophthalmology, and emerging IL-inhibitor classes. The 2024 base also captures a year of unusually strong regulatory momentum, with FDA reaching its 60th cumulative biosimilar approval. For executives, the more important point is that current scale is already large enough to justify dedicated U.S. commercial infrastructure rather than opportunistic distribution-only participation.

The market is projected to reach USD 30,630 Mn by 2030, implying an extended 2025-2030 CAGR of 18.3%. Growth should remain strong, but the mechanism changes over time. Historical expansion came from first-wave launches and rapid substitution in supportive care and oncology, while future growth will rely more on channel access, interchangeability, PBM preference, and specialty portfolio breadth. This means headline growth remains attractive, but execution risk will increasingly shift from approval timing to commercial conversion quality. Companies with payer leverage and multi-molecule field infrastructure should outperform smaller single-asset entrants.

The United States Biosimilar Industry Market expanded at an estimated 30.2% CAGR during 2019-2024, rising from USD 3,000 Mn in 2019 to USD 11,200 Mn in 2024. The strongest step-up came during 2023-2024 as larger immunology and specialty opportunities began to supplement established oncology and G-CSF adoption. Biosimilar savings also rose materially over the same period, reinforcing that this was not only a revenue story but a payer-validated cost-containment story. Historical growth therefore confirms that the market has already crossed the proof-of-concept threshold and is now in a scaled commercialization phase.

The next major profit pool shift is likely to move toward pharmacy-channel and chronic-use biosimilars, especially insulin analogues, while ophthalmology and newer immunology molecules add specialty depth. Insulin and Analogues Biosimilars are the fastest-growing commercial segment in the locked market framework at 24.5% CAGR. Unlike hospital-administered products, pharmacy-dispensed categories can generate recurring refill economics and benefit more directly from interchangeability. At the same time, ophthalmology and post-2024 immunology launches broaden the specialty revenue mix, allowing companies to reuse medical and market-access infrastructure across more molecules and treatment settings.

The biggest risks are not clinical; they are commercial and structural. First, payer and PBM economics can slow conversion even after launch, as shown by adalimumab where the originator retained at least 97% of total volume through March 2024. Second, not every patent expiry becomes a viable biosimilar market. IQVIA found only 12 of 118 biologics losing protection during 2025-2034 had biosimilars in development as of June 2024. Third, interchangeability and substitution remain subject to state law and channel design, creating execution complexity. These risks can delay volume ramp and compress margins simultaneously.

The United States is the largest market among comparable OECD biosimilar markets by a wide margin, but it is not the most mature in molecule-level uptake. The United States combines USD 11,200 Mn of 2024 market size with the highest biologic spending intensity at USD 1,176 per capita in 2023. Yet in adalimumab, U.S. biosimilar uptake was only 2% in Q2 2024, versus 63% in Canada and 90% in the United Kingdom. That combination of scale leadership and lower conversion is strategically important because it suggests the U.S. still offers both present size and future catch-up upside.

The central demand driver is the imbalance between biologic cost concentration and payer affordability pressure. In 2024, biologics represented only 5% of prescriptions but accounted for 51% of total U.S. drug spending. That imbalance makes biosimilars one of the few scalable tools available to reduce specialty spend without reducing access to treatment. The result is persistent interest from Medicare, commercial payers, employers, and health systems, especially as new biologics lose exclusivity. For commercial teams, this means demand is not primarily consumer-led; it is institutionally driven through reimbursement, formulary design, and provider economics.